Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Common Equity: 2020-2024

Historic Common Equity for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Dec 2024 value amounting to $157.5 million.

  • Arcutis Biotherapeutics' Common Equity rose 0.91% to $158.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $158.1 million, marking a year-over-year increase of 0.91%. This contributed to the annual value of $157.5 million for FY2024, which is 77.68% up from last year.
  • Latest data reveals that Arcutis Biotherapeutics reported Common Equity of $157.5 million as of FY2024, which was up 77.68% from $88.7 million recorded in FY2023.
  • Arcutis Biotherapeutics' 5-year Common Equity high stood at $297.7 million for FY2021, and its period low was $88.7 million during FY2023.
  • In the last 3 years, Arcutis Biotherapeutics' Common Equity had a median value of $157.5 million in 2024 and averaged $151.9 million.
  • Per our database at Business Quant, Arcutis Biotherapeutics' Common Equity crashed by 57.69% in 2023 and then surged by 77.68% in 2024.
  • Arcutis Biotherapeutics' Common Equity (Yearly) stood at $270.6 million in 2020, then grew by 10.00% to $297.7 million in 2021, then fell by 29.59% to $209.6 million in 2022, then plummeted by 57.69% to $88.7 million in 2023, then spiked by 77.68% to $157.5 million in 2024.